Intensity Therapeutics Inc
INTS
NASDAQ
Biotechnology
$3.96
USD
-0.04 (-1.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $11.60M
Volume 38.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-11.16M
TTM
+11.2%
YoY
Operating Cash Flow
$-8.95M
TTM
+19.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.2 | 1.2 | 1.6 | 1.3 | 1.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.7 | 2.7 | 3.1 | 2.5 | 3.1 |
Operating Income | -2.7 | -2.7 | -3.1 | -2.5 | -3.1 |
EBITDA | -2.7 | -2.7 | -3.1 | -2.5 | -3.1 |
Other Income / Expense | 0.2 | 0.0 | 0.0 | -0.0 | 0.0 |
Total Other Income / Expense | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
Income Before Income Taxes | -2.5 | -2.7 | -3.1 | -2.4 | -3.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.5 | -2.7 | -3.1 | -2.4 | -3.0 |
Consolidated Net Income / Loss | -2.5 | -2.7 | -3.1 | -2.4 | -3.0 |
Net Income Attributable to Common Shareholders | -2.5 | -2.7 | -3.1 | -2.4 | -3.0 |
Basic EPS | -$3.36 | -$1.50 | -$1.30 | -$0.96 | -$1.11 |
Diluted EPS | -$3.36 | -$1.50 | -$1.30 | -$0.96 | -$1.11 |
Basic Shares Outstanding | 0.8M | 1.7M | 2.3M | 2.5M | 2.7M |
Diluted Shares Outstanding | 0.8M | 1.7M | 2.3M | 2.5M | 2.7M |